Special Report on Neuroscience: Demystifying psychedelics
Researchers add analysis to the mix to move beyond anecdotes
Neuroscience
Deep brain stimulation for Parkinson's disease
New discoveries suggest it is on par with therapeutics and speeds the process of recovery and adoption of personalized treatment
Bringing siRNA across the barrier
Bioasis announces publication evaluating CNS delivery of siRNA via the company’s xB³ platform
Focus Feature on Neuroscience: Preclinical progress on neurodegeneration
Making the rounds of brain-related therapeutic and diagnostic R&D, with a focus on neurodegenerative disease and dementia
Brain biomarkers for depression and trauma
Combining machine learning and EEG may have identified an imaging biomarker for better treating PTSD and MDD
Clues to complexity
Study determines genetic variants of PTSD
BetterLife and UCSD partner on LSD derivative
BetterLife enters research agreement with UCSD for TD-0148A behavioral pharmacology studies
Cholesterol may be key to new Alzheimer’s and diabetes therapies
University of Arizona researcher looks beyond traditional causes to find novel therapies
Could DMT be beneficial in stroke recovery?
Algernon Pharmaceuticals submits pre-IND meeting request for clinical research program in DMT for stroke
IntelGenx and atai partner up on psychedelics
IntelGenx announces strategic partnership with atai Life Sciences; agreement also includes equity investment by atai
Data to build on
Yumanity's YTX-7739 prevents motor function deficits, leads to improved survival of dopaminergic neurons in Parkinson’s disease mouse model
